Taurus Asset Management LLC Sells 650 Shares of Thermo Fisher Scientific Inc. (TMO)
Taurus Asset Management LLC reduced its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.7% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 89,801 shares of the medical research company’s stock after selling 650 shares during the quarter. Thermo Fisher Scientific accounts for approximately 2.6% of Taurus Asset Management LLC’s holdings, making the stock its 8th largest holding. Taurus Asset Management LLC’s holdings in Thermo Fisher Scientific were worth $16,990,000 at the end of the most recent reporting period.
Several other large investors also recently made changes to their positions in TMO. Chicago Partners Investment Group LLC purchased a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at about $108,000. Shine Investment Advisory Services Inc. purchased a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at about $113,000. Ropes Wealth Advisors LLC raised its holdings in shares of Thermo Fisher Scientific by 15.8% during the 2nd quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock valued at $124,000 after buying an additional 97 shares during the period. Atlantic Trust LLC purchased a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at about $138,000. Finally, Grove Bank & Trust raised its holdings in shares of Thermo Fisher Scientific by 19.9% during the 2nd quarter. Grove Bank & Trust now owns 860 shares of the medical research company’s stock valued at $150,000 after buying an additional 143 shares during the period. Institutional investors and hedge funds own 86.05% of the company’s stock.
In other news, CEO Marc N. Casper sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $191.74, for a total value of $9,587,000.00. Following the completion of the sale, the chief executive officer now directly owns 302,577 shares in the company, valued at approximately $58,016,113.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.49% of the stock is currently owned by insiders.
Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The business had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $5.03 billion. During the same period in the previous year, the business earned $2.03 EPS. The business’s quarterly revenue was up 13.9% on a year-over-year basis. equities analysts anticipate that Thermo Fisher Scientific Inc. will post 9.36 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Monday, January 15th. Stockholders of record on Friday, December 15th will be issued a $0.15 dividend. The ex-dividend date is Thursday, December 14th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.31%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.19%.
Several research firms have issued reports on TMO. Zacks Investment Research downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Monday, September 18th. Barclays restated an “overweight” rating and set a $215.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a report on Monday, September 25th. Argus restated a “buy” rating on shares of Thermo Fisher Scientific in a report on Tuesday, August 22nd. They noted that the move was a valuation call. Jefferies Group restated a “hold” rating and set a $195.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, September 28th. Finally, Morgan Stanley restated an “overweight” rating and set a $220.00 price objective on shares of Thermo Fisher Scientific in a report on Wednesday, September 6th. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $205.21.
TRADEMARK VIOLATION WARNING: This piece of content was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/12/20/taurus-asset-management-llc-sells-650-shares-of-thermo-fisher-scientific-inc-tmo.html.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.